logo

For the Inventor, By the Inventor

Tokyo, Japan

Teijin Pharma Limited


USPTO Granted Patents = 127

% Expired Patents = 33.9



Forward Citations = 1,091

Loading Chart...
Loading Chart...

308 inventors (with patents filed for the assignee):

goldMedal Keiko Omura (11 out of 11 patents)

silverMedal Shinya Fujimoto (10 out of 10 patents)

bronzeMedal Gen Unoki (9 out of 10 patents)

4.  Takamitsu Okayama (7 out of 7 patents)

5.  Yoshimasa Takahashi (7 out of 14 patents)

6.  Hideo Nawata (7 out of 7 patents)

7.  Hiroshi H Eguchi (7 out of 48 patents)

8.  Akihiro Maeda (6 out of 17 patents)

9.  Akira Tanokura (6 out of 7 patents)

10.  Masahide Takishita (6 out of 6 patents)

11.  Tongoh Chin (6 out of 6 patents)

12.  Fumi Fujita (5 out of 5 patents)

13.  Jun Takeda (5 out of 85 patents)

14.  Sadayoshi Matsumoto (5 out of 5 patents)

15.  Hideharu Shimura (5 out of 7 patents)


Core Competencies:
Oxygen Concentrator
Phototherapy Device
Humanized Antibody
Respiratory System
Nitric Oxide Administration
Benzimidazole Derivatives
Transcranial Magnetic Stimulation
Therapeutic Devices
Training Apparatus
Medical Instruments
Gas Supply Device
Rehabilitation Assistance

127 patents:

1. 12759982 - Aryl or heteroaryl derivative (2026-10-13),
2. 12502550 - Light beam irradiation apparatus (2025-12-23),
3. 12492185 - Benzimidazole derivatives and their uses (2025-12-09),
4. 12465714 - Oxygen concentrator, control method, and control program (2025-11-11),
5. 12458916 - Oxygen concentration device (2025-11-04),
6. 12415089 - Phototherapy device and method of operation of phototherapy device (2025-09-16),
7. 12227563 - Anti-IGF-I receptor humanized antibody (2025-02-18),
8. 12151123 - Phototherapy device (2024-11-26),
9. 12109359 - Oxygen supply device and method for controlling same (2024-10-08),
10. 11951261 - Nitric oxide administration device (2024-04-09),
11. 11951256 - Oxygen therapy system (2024-04-09),
12. 11739143 - Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same (2023-08-29),
13. 11690971 - Exacerbation predicting device, oxygen concentrating device, and exacerbation predicting system (2023-07-04),
14. 11667707 - SPNS2 neutralizing antibody (2023-06-06),
15. 11666718 - Respiratory information acquisition device and respiratory information acquisition method (2023-06-06),
Company Overview
Teijin Pharma Limited, headquartered in Tokyo, specializes in the development and manufacturing of advanced medical devices, particularly in the field of oxygen concentration. The company focuses on innovative technologies such as oxygen concentrators and phototherapy devices, alongside therapeutic solutions involving humanized antibodies and nitric oxide administration. Teijin Pharma is also engaged in research related to benzimidazole derivatives and transcranial magnetic stimulation, contributing significantly to respiratory health and therapeutic device advancements.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

127 Patents

#479 in Tokyo

#974 in Japan

#6,324 in the World

Tokyo, JP
Tokyo, Japan

Teijin Pharma Limited

Forward Citations = 1,091

308 inventors:

goldMedal Keiko Omura (11 out of 11 patents)

silverMedal Shinya Fujimoto (10 out of 10 patents)

bronzeMedal Gen Unoki (9 out of 10 patents)

4.  Takamitsu Okayama (7 out of 7 patents)

5.  Yoshimasa Takahashi (7 out of 14 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Teijin Pharma Limited. Retrieved from https://idiyas.com/company/teijin-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…